Q-omics provides the consensus-scored NCBP2L profile across patient tissues and cancer cell-line models. NCBP2L expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NCBP2L is differentially expressed in 15, with the highest sampling consensus in LUSC. Additionally, NCBP2L RNA expression shows 9,128 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight ACC, LUSC, and BRCA as cancer lineages where NCBP2L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCBP2L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCBP2L survival associations across molecular data types. NCBP2L RNA expression shows survival associations in the most cancer types (15), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCBP2L RNA expression–survival associations across cancer types. High NCBP2L expression shows unfavorable associations in LGG and ESCA, but favorable associations in ACC, SKCM, LIHC and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NCBP2L RNA expression.
This table summarizes NCBP2L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for NCBP2L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCBP2L shows lower tumor expression in LUSC, KICH, LUAD and UCEC and higher tumor expression in BRCA and PRAD. The LUSC box plot shows higher NCBP2L RNA expression in normal versus tumor tissue (log2 FC = −0.402, t-test p < 0.001).
This table shows molecular features associated with NCBP2L in patient tissues and cancer cell lines. In patient samples, NCBP2L shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, NCBP2L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST.
